FDAnews
www.fdanews.com/articles/178692-lundbeck-alzheimers-drug-fails-to-meet-phase-iii-endpoints

Lundbeck Alzheimer’s Drug Fails to Meet Phase III Endpoints

October 4, 2016

Lundbeck’s idalopirdine failed to meet the primary endpoint of a Phase III trial in Alzheimer’s disease, showing a weak efficacy profile in two dosages combined with donepezil.

The drug aslo missed secondary endpoints, showing no changes compared to placebo. Results showed that idalopirdine was safe and well tolerated.

Idalopirdine demonstrated positive results in a Phase II trial as adjunctive therapy, and was granted a Fast Track designation by the FDA. Two separate Phase III trials, evaluating combinations with donepezil, galantamine, or rivastigmine, are ongoing, and Lundbeck expects results in the first quarter of 2017.

View today's stories